Fc-fusion proteins and FcRn: Structural insights for longer-lasting and more effective therapeutics

Critical Reviews in Biotechnology

Volumn 35, Issue 2, 2015, Pages 235-254

  Rath, Timo ^a   Baker, Kristi ^a   Dumont, Jennifer A ^b   Peters, Robert T ^b   Jiang, Haiyan ^b   Qiao, Shuo Wang ^c   Lencer, Wayne I ^a   Pierce, Glenn F ^b   Blumberg, Richard S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BIOGEN   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Fc fusion proteins; IgG; Mucosal drug delivery; Neonatal Fc receptor; Therapeutic antibody

Indexed keywords

CONTROLLED DRUG DELIVERY; TARGETED DRUG DELIVERY;

CLINICAL USE; FC FUSION PROTEINS; IN-VIVO; NEONATAL FC RECEPTORS; STRUCTURAL INSIGHTS; STRUCTURE-FUNCTION RELATIONSHIP; THERAPEUTIC ANTIBODIES; THERAPEUTIC BENEFITS;

PROTEINS;

ABATACEPT; AFLIBERCEPT; ALEFACEPT; BELATACEPT; BLISIBIMOD; ERYTHROPOIETIN; ETANERCEPT; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; RILONACEPT; ROMIPLOSTIM; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1;

AGE RELATED MACULAR DEGENERATION; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; HOMEOSTASIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGENICITY; IN VIVO STUDY; KIDNEY GRAFT REJECTION; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PROCESSING; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; IMMUNOTHERAPY; MOLECULAR MODEL; MOUSE;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; MICE; MODELS, MOLECULAR; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS;

EID: 84932132043     PISSN: 07388551     EISSN: 15497801     Source Type: Journal    
DOI: 10.3109/07388551.2013.834293     Document Type: Review

References (226)

1. Abrahamson DR, Powers A, Rodewald R. (1979). Intestinal absorption of immune complexes by neonatal rats: a route of antigen transfer from mother to young. Science, 206, 567-9.
2. Adamski FM, King AT, Demmer J. (2000). Expression of the Fc receptor in the mammary gland during lactation in the marsupial Trichosurus vulpecula (brushtail possum). Mol Immunol, 37, 435-44.
3. Aggarwal S. (2011). What's fueling the biotech engine - 2010 to 2011. Nature Biotechnol, 29, 1083-9.
4. Ahouse JJ, Hagerman CL, Mittal P, et al. (1993). Mouse MHC class Ilike Fc receptor encoded outside the MHC. J Immunol, 151, 6076-88.
5. Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. (2007). Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol, 179, 4580-8.
6. Amevive. (2011). Prescribing information. Available from: http:// www.astellas.us/docs/amevive.pdf [last accessed 24 Apr 2012].
7. Anderson CL, Chaudhury C, Kim J, et al. (2006). Perspective - FcRn transports albumin: relevance to immunology and medicine. Trends Immunol, 27, 343-8.
8. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. (2011). Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature, 475, 110-3.
9. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. (2008). Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A, 105, 19571-8.
10. Arcalyst. (2010). Prescribing information. Available from: http:// www.regeneron.com//ArcalystPI-US-Summary-EMEA/Arcalyst PI- June-2010r3-1.pdf [last accessed 24 Apr 2012].
11. Arnold JN, Wormald MR, Sim RB, et al. (2007). The impact of glycosylation on the biological function and structure of human immunoglobulins. Ann Rev Immunol, 25, 21-50.
12. Bai Y, Ye L, Tesar DB, et al. (2011). Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci U S A, 108, 18406-11.
13. Baker K, Qiao SW, Kuo T, et al. (2009). Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn. Semin Immunopathol, 31, 223-36.
14. Baker K, Qiao SW, Kuo TT, et al. (2011). Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells. Proc Natl Acad Sci U S A, 108, 9927-32.
15. Baker K, Rath T, Lencer WI, et al. (2012). Cross-presentation of IgGcontaining immune complexes. Cell Mol Life Sci, 70, 1319-34.
16. Beck A. (2011). Biosimilar, biobetter and next generation therapeutic antibodies. MAbs, 3, 107-10.
17. Beck A, Wurch T, Bailly C, Corvaia, N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol, 10, 345-52.
18. Beck A, Wurch T, Corvaia N. (2008). Therapeutic antibodies and derivatives: from the bench to the clinic. Curr Pharm Biotechnol, 9, 421-2.
19. Ben Suleiman Y, Yoshida M, Nishiumi S, et al. (2012). Neonatal Fc receptor for IgG (FcRn) expressed in the gastric epithelium regulates bacterial infection in mice. Mucosal Immunol, 5, 87-98.
20. Bitonti AJ, Dumont JA. (2006). Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv Drug Deliv Rev, 58, 1106-18.
21. Bitonti AJ, Dumont JA, Low SC, et al. (2004). Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A, 101, 9763-8.
22. Borel Y. (1980). Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression. Immunol Rev, 50, 71-104.
23. Borys MC, Dalal NG, Abu-Absi NR, et al. (2010). Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol Bioeng, 105, 1048-57.
24. Bracewell C, Isaacs JD, Emery P, Ng WF. (2009). Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther, 9, 909-19.
25. Brambell FW. (1963). Resemblances between passive anaphylactic sensitization and transmission of passive immunity. Nature, 199, 1164-6.
26. Brambell FW, Hemmings WA, Morris IG. (1964). A theoretical model of gamma-globulin catabolism. Nature, 203, 1352-4.
27. Burge DJ, Bookbinder SA, Kivitz AJ, et al. (2008). Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. Clin Ther, 30, 1806-16.
28. Burmeister WP, Gastinel LN, Simister NE, et al. (1994a). Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor. Nature, 372, 336-43.
29. Burmeister WP, Huber AH, Bjorkman PJ. (1994b). Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature, 372, 379-83.
30. Bussel JB, Kuter DJ, Pullarkat V, et al. (2009). Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood, 113, 2161-71.
31. Byrn RA, Mordenti J, Lucas C, et al. (1990). Biological properties of a CD4 immunoadhesin. Nature, 344, 667-70.
32. Capon DJ, Chamow SM, Mordenti J, et al. (1989). Designing CD4 immunoadhesins for AIDS therapy. Nature, 337, 525-31.
33. Chamian F, Lowes MA, Lin SL, et al. (2005). Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A, 102, 2075-80.
34. Chan AC, Carter PJ. (2010). Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol, 10, 301-16.
35. Chaudhury C, Mehnaz S, Robinson JM, et al. (2003). The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med, 197, 315-22.
36. Chu QS. (2009). Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther, 9, 263-71.
37. Ciombor KK, Berlin J, Chan E. (2013). Aflibercept. Clin Cancer Res, 19, 1920-5.
38. Coleman RL, Duska LR, Ramirez PT, et al. (2011). Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol, 12, 1109-17.
39. Collen D, Bernaerts R, Declerck P, et al. (1996a). Recombinant staphylokinase variants with altered immunoreactivity. I: construction and characterization. Circulation, 94, 197-206.
40. Collen D, Moreau H, Stockx L, Vanderschueren S. (1996b). Recombinant staphylokinase variants with altered immunoreactivity. II: thrombolytic properties and antibody induction. Circulation, 94, 207-16.
41. Cwirla SE, Balasubramanian P, Duffin DJ, et al. (1997). Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science, 276, 1696-9.
42. Dall'acqua WF, Kiener PA, Wu H. (2006). Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem, 281, 23514-24.
43. Dall'acqua WF, Woods RM, Ward ES, et al. (2002). Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol, 169, 5171-80.
44. Dall'era M, Chakravarty E, Wallace D, et al. (2007). Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum, 56, 4142-50.
45. Datta-Mannan A, Witcher DR, Tang Y, et al. (2007). Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem, 282, 1709-17.
46. De Groot AS, Martin W. (2009). Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin Immunol, 131, 189-201.
47. De Groot AS, Moise L, Mcmurry JA, et al. (2008). Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood, 112, 3303-11.
48. De Groot AS, Scott DW. (2007). Immunogenicity of protein therapeutics. Trends Immunol, 28, 482-90.
49. De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, et al. (2009). Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis, 68, 531-5.
50. Deisenhofer J. (1981). Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. Biochemistry, 20, 2361-70.
51. Deng R, Loyet KM, Lien S, et al. (2010). Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos, 38, 600-5.
52. Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, et al. (2012). A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Br J Cancer, 107, 604-11.
53. Dickinson BL, Badizadegan K, Wu Z, et al. (1999). Bidirectional FcRndependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest, 104, 903-11.
54. Dore RK, Mathews S, Schechtman J, et al. (2007). The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol, 25, 40-6.
55. Doronina SO, Mendelsohn BA, Bovee TD, et al. (2006). Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem, 17, 114-24.
56. Dumont JA, Bitonti AJ, Clark D, et al. (2005). Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med, 18, 294-303.
57. Dumont JA, Liu T, Low SC, et al. (2012). Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 119, 3024-30.
58. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006). Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs, 20, 151-60.
59. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2009). Monomeric Fc fusion molecules, in: therapeutic monoclonal antibodies: from bench to clinic. Hoboken, NJ: John Wiley & Sons Inc.
60. Economides AN, Carpenter LR, Rudge JS, et al. (2003). Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med, 9, 47-52.
61. Enbrel®. (2011). Prescribing Information. Available from: http://pi.amgen.com/united-states/enbrel/derm/enbrel-pi.pdf [last accessed 24 Apr 2012].
62. Ephrem A, Chamat S, Miquel C, et al. (2008). Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood, 111, 715-22.
63. Eylea. (2011). Prescribing information. Available from: http://www.regeneron.com/Eylea/eylea-fpi.pdf [last accessed 24 Apr 2012].
64. Firan M, Bawdon R, Radu C, et al. (2001). The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol, 13, 993-1002.
65. Fleischmann RM, Cohen SB, Stanley B, et al. (2010). Evidence of peripheral B cell depletion in subjects with controlled lupus erythematosus (SLE) following subcutaneous administration of SBI-087 (Abstract). Arthritis Rheum, 62, 1154.
66. Freyer G, Isambert N, You B, et al. (2012). Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. Br J Cancer, 107, 598-603.
67. Genovese MC, Kinnman N, De la Bourdonnaye G, et al. (2011). Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum, 63, 1793-803.
68. Ghaderi D, Taylor RE, Padler-Karavani V, et al. (2010). Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nature Biotechnol, 28, 863-7.
69. Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. (2012). Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnol Genet Eng Rev, 28, 147-75.
70. Ghetie V, Hubbard JG, Kim JK, et al. (1996). Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol, 26, 690-6.
71. Ghose S, Hubbard B, Cramer SM. (2006). Evaluation and comparison of alternatives to protein A chromatography mimetic and hydrophobic charge induction chromatographic stationary phases. J Chromatogr A, 1122, 144-52.
72. Ginzler EM, Wax S, Rajeswaran A, et al. (2012). Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther, 14, R33.
73. Gordon KB, Langley RG. (2003). Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol, 2, 624-8.
74. Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL. (2006). Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol, 43, 1462-73.
75. Haggerty HG, Abbott MA, Reilly TP, et al. (2007). Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol, 34, 2365-73.
76. Hayden-Ledbetter MS, Cerveny CG, Espling E, et al. (2009). CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res, 15, 2739-46.
77. He Y, Bjorkman PJ. (2011). Structure of FcRY, an avian immunoglobulin receptor related to mammalian mannose receptors, and its complex with IgY. Proc Natl Acad Sci U S A, 108, 12431-6.
78. Hinton PR, Johlfs MG, Xiong JM, et al. (2004). Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem, 279, 6213-6.
79. Hinton PR, Xiong JM, Johlfs MG, et al. (2006). An engineered human IgG1 antibody with longer serum half-life. J Immunol, 176, 346-56.
80. Hoffman HM, Throne ML, Amar NJ, et al. (2008). Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum, 58, 2443-52.
81. Holash J, Davis S, Papadopoulos N, et al. (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A, 99, 11393-8.
82. Huang C. (2009). Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol, 20, 692-9.
83. Huber AH, Kelley RF, Gastinel LN, Bjorkman PJ. (1993). Crystallization and stoichiometry of binding of a complex between a rat intestinal Fc receptor and Fc. J Mol Biol, 230, 1077-83.
84. Huber R, Deisenhofer J, Colman PM, et al. (1976). Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature, 264, 415-20.
85. Hwang WY, Foote J. (2005). Immunogenicity of engineered antibodies. Methods, 36, 3-10.
86. Igawa T, Ishii S, Tachibana T, et al. (2010). Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nature Biotechnol, 28, 1203-7.
87. Isambert N, Freyer G, Zanetta S, et al. (2012). Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res, 18, 1743-50.
88. Israel EJ, Wilsker DF, Hayes KC, et al. (1996). Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology, 89, 573-8.
89. Iyer U, Kadambi VJ. (2011). Antibody drug conjugates - Trojan horses in the war on cancer. J Pharmacol Toxicol Methods, 64, 207-12.
90. Jazayeri JA, Carroll GJ. (2008). Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs, 22, 11-26.
91. Jiang XR, Song A, Bergelson S, et al. (2011). Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov, 10, 101-11.
92. Junghans RP, Anderson CL. (1996). The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A, 93, 5512-6.
93. Kacskovics I, Mayer B, Kis Z, et al. (2006). Cloning and characterization of the dromedary (Camelus dromedarius) neonatal Fc receptor (drFcRn). Dev Comp Immunol, 30, 1203-15.
94. Kacskovics I, Wu Z, Simister NE, et al. (2000). Cloning and characterization of the bovine MHC class I-like Fc receptor. J Immunol, 164, 1889-97.
95. Kandil E, Egashira M, Miyoshi O, et al. (1996). The human gene encoding the heavy chain of the major histocompatibility complex class I-like Fc receptor (FCGRT) maps to 19q13.3. Cytogenet Cell Genet, 73, 97-8.
96. Kaneko Y, Nimmerjahn F, Ravetch JV. (2006). Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313, 670-3.
97. Kemshead JT, Hopkins K. (1993). Uses and limitations of monoclonal antibodies (MoAbs) in the treatment of malignant disease: a review. J R Soc Med, 86, 219-24.
98. Kessel A, Ammuri H, Peri R, et al. (2007). Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol, 179, 5571-5.
99. Keystone EC, Schiff MH, Kremer JM, et al. (2004). Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum, 50, 353-63.
100. Kim J, Bronson CL, Hayton WL, et al. (2005). Albumin turnover: FcRnmediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol, 290, G352-60.
101. Kim J, Bronson CL, Wani MA, et al. (2008). Beta 2-microglobulin deficient mice catabolize IgG more rapidly than FcRn- alpha-chain deficient mice. Exp Biol Med, 233, 603-9.
102. Kim J, Hayton WL, Robinson JM, Anderson CL. (2007). Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanismbased model. Clin Immunol, 122, 146-55.
103. Kim JK, Firan M, Radu CG, et al. (1999). Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur J Immunol, 29, 2819-25.
104. Kim JK, Tsen MF, Ghetie V, Ward ES. (1994). Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol, 24, 2429-34.
105. Kobayashi K, Qiao SW, Yoshida M, et al. (2009). An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology, 137, 1746-56 e1.
106. Kohler G, Milstein C. (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 256, 495-7.
107. Koren E, De Groot AS, Jawa V, et al. (2007). Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clinical Immunol, 124, 26-32.
108. Kremer JM, Westhovens R, Leon M, et al. (2003). Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New Engl J Med, 349, 1907-15.
109. Krueger GG, Papp KA, Stough DB, et al. (2002). A randomized, doubleblind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol, 47, 821-33.
110. Kuo TT, De Muinck EJ, Claypool SM, et al. (2009). N-glycan moieties in neonatal Fc receptor determine steady-state membrane distribution and directional transport of IgG. J Biol Chem, 284, 8292-300.
111. Larsen CP, Pearson TC, Adams AB, et al. (2005). Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant, 5, 443-53.
112. Leach JL, Sedmak DD, Osborne JM, et al. (1996). Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J Immunol, 157, 3317-22.
113. Lebwohl M, Christophers E, Langley R, et al. (2003). An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol, 139, 719-27.
114. Lei TC, Scott DW. (2005). Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood, 105, 4865-70.
115. Li Z, Palaniyandi S, Zeng R, et al. (2011). Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A, 108, 4388-93.
116. Lonberg N. (2008). Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol, 20, 450-9.
117. Lovell DJ, Giannini EH, Reiff A, et al. (2000). Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. New Engl J Med, 342, 763-9.
118. Low SC, Nunes SL, Bitonti AJ, Dumont JA. (2005). Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod, 20, 1805-13.
119. Lowe NJ, Gonzalez J, Bagel J, et al. (2003). Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol, 42, 224-30.
120. Lu L, Palaniyandi S, Zeng R, et al. (2011). A neonatal Fc receptortargeted mucosal vaccine strategy effectively induces HIV-1 antigenspecific immunity to genital infection. J Virol, 85, 10542-53.
121. Magdelaine-Beuzelin C, Vermeire S, Goodall M, et al. (2009). IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics, 19, 383-7.
122. Mahlangu J, Powell J, Ragni M, et al. (2013). Phase 3 clinical study of recombinant Fc fusion factor VIII (rFVIIIFc) demonstrated safety, efficacy and improved pharmacokinetics (A-LONG). Haemophilia, 19, 70.
123. Martin WL, West Jr AP, Gan L, Bjorkman PJ. (2001). Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pHdependent binding. Mol Cell, 7, 867-77.
124. Mayer B, Zolnai A, Frenyo LV, et al. (2002a). Localization of the sheep FcRn in the mammary gland. Vet Immunol Immunopathol, 87, 327-30.
125. Mayer B, Zolnai A, Frenyo LV, et al. (2002b). Redistribution of the sheep neonatal Fc receptor in the mammary gland around the time of parturition in ewes and its localization in the small intestine of neonatal lambs. Immunology, 107, 288-96.
126. Mayer L, Kaser A, Blumberg RS. (2012). Dead on arrival: understanding the failure of CTLA4-immunoglobulin therapy in inflammatory bowel disease. Gastroenterology, 143, 13-7.
127. Mease P, Genovese MC, Gladstein G, et al. (2011). Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum, 63, 939-48.
128. Medesan C, Matesoi D, Radu C, et al. (1997). Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG1. J Immunol, 158, 2211-7.
129. Merrill JT, Burgos-Vargas R, Westhovens R, et al. (2010). The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 62, 3077-87.
130. Molineux G, Newland A. (2010). Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol, 150, 9-20.
131. Montoyo HP, Vaccaro C, Hafner M, et al. (2009). Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A, 106, 2788-93.
132. Moreland L, Bate G, Kirkpatrick P. (2006). Abatacept. Nature Rev Drug Discov, 5, 185-6.
133. Munafo A, Priestley A, Nestorov I, et al. (2007). Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol, 63, 647-56.
134. Nelson AL, Dhimolea E, Reichert JM. (2010). Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov, 9, 767-74.
135. Nimmerjahn F, Ravetch JV. (2007). The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med, 204, 11-15.
136. Nplate. (2011). Prescribing information. Available from: http://pi.amgen.com/united-states/nplate/nplate-pi-hcp-english.pdf [last accessed 24 Apr 2012].
137. Nulojix. (2011). Prescribing Information. Available from: http://packageinserts.bms.com/pi/pi-nulojix.pdf [last accessed 24 Apr 2012].
138. Ober RJ, Martinez C, Lai X, et al. (2004a). Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci U S A, 101, 11076-81.
139. Ober RJ, Martinez C, Vaccaro C, et al. (2004b). Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol, 172, 2021-9.
140. Ober RJ, Radu CG, Ghetie V, Ward ES. (2001). Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol, 13, 1551-9.
141. Oganesyan V, Damschroder MM, Woods RM, et al. (2009). Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol, 46, 1750-5.
142. Oldenburg J, Pavlova A. (2006). Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia, 12, 15-22.
143. Orban T, Bundy B, Becker DJ, et al. (2011). Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet, 378, 412-9.
144. Orencia. (2011). Prescribing Information. Available from: http://packageinserts.bms.com/pi/pi-orencia.pdf [last accessed 24 Apr 2012].
145. Padler-Karavani V, Yu H, Cao H, et al. (2008). Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology, 18, 818-30.
146. Papadopoulos N, Martin J, Ruan Q, et al. (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15, 171-85.
147. Patel DA, Puig-Canto A, Challa DK, et al. (2011). Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. J Immunol, 187, 1015-22.
148. Patel TP, Parekh RB, Moellering BJ, Prior CP. (1992). Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem J, 285, 839-45.
149. Pena-Rossi C, Nasonov E, Stanislav M, et al. (2009). An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus, 18, 547-55.
150. Peters RT, Low SC, Kamphaus GD, et al. (2010). Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood, 115, 2057-64.
151. Peters Jr T. (1977). Serum albumin: recent progress in the understanding of its structure and biosynthesis. Clin Chem, 23, 5-12.
152. Peters Jr T. (1985). Serum albumin. Adv Protein Chem, 37, 161-245.
153. Petkova SB, Akilesh S, Sproule TJ, et al. (2006). Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol, 18, 1759-69.
154. Powell J, Ozelo M, Pasi J, et al. (2013). Safety, efficacy, and improved pharmacokinetics (PK) demonstrated in a phase 3 clinical trial of extended half life recombinant Fc fusion factor IX (B-LONG). Haemophilia, 19, 76.
155. Powell JS, Josephson NC, Quon D, et al. (2012). Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, 119, 3031-7.
156. Qiao SW, Kobayashi K, Johansen FE, et al. (2008). Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci U S A, 105, 9337-42.
157. Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. (1995). Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry, 34, 14649-57.
158. Reichert JM. (2008). Monoclonal antibodies as innovative therapeutics. Curr Pharmaceut Biotechnol, 9, 423-30.
159. Reichert JM. (2010). Antibodies to watch in 2010. MAbs, 2, 84-100.
160. Reichert JM. (2012). Which are the antibodies to watch in 2012? MAbs, 4, 1-3.
161. Rilonacept-Smpc. (2009). Summary of product characteristics. Available from: http://www.regeneron.com/ArcalystPI-US-Summary-EMEA/emea-combined-rilonaceptSmPCFeb2012.pdf [last accessed 18 Apr 2012].
162. Roberts JL, Ortonne JP, Tan JK, et al. (2010). The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis. J Am Acad Dermatol, 62, 968-78.
163. Rodewald R. (1973). Intestinal transport of antibodies in the newborn rat. J Cell Biol, 58, 189-211.
164. Rodewald R. (1976). pH-dependent binding of immunoglobulins to intestinal cells of the neonatal rat. J Cell Biol, 71, 666-9.
165. Rodewald R. (1980). Distribution of immunoglobulin G receptors in the small intestine of the young rat. J Cell Biol, 85, 18-32.
166. Rodewald R, Kraehenbuhl JP. (1984). Receptor-mediated transport of IgG. J Cell Biol, 99, 159s-64s.
167. Roopenian DC, Akilesh S. (2007). FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol, 7, 715-25.
168. Roopenian DC, Christianson GJ, Sproule TJ, et al. (2003). The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol, 170, 3528-33.
169. Sanchez LM, Penny DM, Bjorkman PJ. (1999). Stoichiometry of the interaction between the major histocompatibility complex-related Fc receptor and its Fc ligand. Biochemistry, 38, 9471-6.
170. Sandborn WJ, Colombel JF, Sands BE, et al. (2012). Abatacept for Crohn's disease and ulcerative colitis. Gastroenterology, 143, 62-69 e4.
171. Schnulle PM, Hurley WL. (2003). Sequence and expression of the FcRn in the porcine mammary gland. Vet Immunol Immunopathol, 91, 227-31.
172. Schuck P, Radu CG, Ward ES. (1999). Sedimentation equilibrium analysis of recombinant mouse FcRn with murine IgG1. Mol Immunol, 36, 1117-25.
173. Schultze HE, Heremans JF. (1966). Molecular biology of human proteins: with special reference to plasma proteins. Nature and metabolism of extracellular proteins. New York: Elsevier.
174. Scott DW, De Groot AS. (2010). Can we prevent immunogenicity of human protein drugs? Ann Rheum Dis, 69, i72-6.
175. Senter PD. (2009). Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol, 13, 235-44.
176. Shapiro AD, Ragni MV, Valentino LA, et al. (2012). Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood, 119, 666-72.
177. Shields RL, Namenuk AK, Hong K, et al. (2001). High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem, 276, 6591-604.
178. Simister NE, Mostov KE. (1989). An Fc receptor structurally related to MHC class I antigens. Nature, 337, 184-7.
179. Simister NE, Rees AR. (1985). Isolation and characterization of an Fc receptor from neonatal rat small intestine. Eur J Immunol, 15, 733-8.
180. Simister NE, Story CM, Chen HL, Hunt JS. (1996). An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol, 26, 1527-31.
181. Sockolosky JT, Tiffany MR, Szoka FC. (2012). Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A, 109, 16095-100.
182. Spiekermann GM, Finn PW, Ward ES, et al. (2002). Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med, 196, 303-10.
183. Stahl N, Radin A, Mellis S. (2009). Rilonacept - CAPS and beyond. Ann New York Acad Sci, 1182, 124-34.
184. Stohl W. (2012). Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr Rheumatol Rep, 14, 303-9.
185. Stohl W, Hilbert DM. (2012). The discovery and development of belimumab: the anti-BLyS-lupus connection. Nature Biotechnol, 30, 69-77.
186. Story CM, Mikulska JE, Simister NE. (1994). A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med, 180, 2377-81.
187. Strober BE, Menon K. (2007). Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther, 20, 270-6.
188. Sutton BJ, Phillips DC. (1983). The three-dimensional structure of the carbohydrate within the Fc fragment of immunoglobulin G. Biochem Soc Trans, 11, 130-2.
189. Tak PP, Thurlings RM, Rossier C, et al. (2008). Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, doubleblind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum, 58, 61-72.
190. Tangri S, Licalsi C, Sidney J, Sette A. (2002). Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Curr Med Chem, 9, 2191-9.
191. Tangvoranuntakul P, Gagneux P, Diaz S, et al. (2003). Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A, 100, 12045-50.
192. Tao MH, Morrison SL. (1989). Studies of aglycosylated chimeric mousehuman IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol, 143, 2595-601.
193. Tesar DB, Cheung EJ, Bjorkman PJ. (2008). The chicken yolk sac IgY receptor, a mammalian mannose receptor family member, transcytoses IgY across polarized epithelial cells. Mol Biol Cell, 19, 1587-93.
194. Tyring S, Gordon KB, Poulin Y, et al. (2007). Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol, 143, 719-26.
195. Tzaban S, Massol RH, Yen E, et al. (2009). The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol, 185, 673-84.
196. Vaccaro C, Bawdon R, Wanjie S, et al. (2006). Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A, 103, 18709-14.
197. Vallee S, Rakhe S, Reidy T, et al. (2012). Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway. J Interferon Cytokine Res, 32, 178-84.
198. van Vollenhoven RF, Kinnman N, Vincent E, et al. (2011). Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum, 63, 1782-92.
199. Vaughn DE, Bjorkman PJ. (1998). Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure, 6, 63-73.
200. Vaughn DE, Milburn CM, Penny DM, et al. (1997). Identification of critical IgG binding epitopes on the neonatal Fc receptor. J Mol Biol, 274, 597-607.
201. Viglietta V, Bourcier K, Buckle GJ, et al. (2008). CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology, 71, 917-24.
202. Vincenti F, Blancho G, Durrbach A, et al. (2010). Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol, 21, 1587-96.
203. Waldmann TA, Terry WD. (1990). Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin. J Clin Investig, 86, 2093-8.
204. Walsh G. (2010). Post-translational modifications of protein biopharmaceuticals. Drug Discov Today, 15, 773-80.
205. Walsh G, Jefferis R. (2006). Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol, 24, 1241-52.
206. Wang TF, Lockhart AC. (2012). Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol, 6, 19-30.
207. Wang W, Lu P, Fang Y, et al. (2011). Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos, 39, 1469-77.
208. Wani MA, Haynes LD, Kim J, et al. (2006). Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A, 103, 5084-9.
209. Ward ES, Martinez C, Vaccaro C, et al. (2005). From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell, 16, 2028-38.
210. Ward ES, Ober RJ. (2009). Chapter 4: multitasking by exploitation of intracellular transport functions the many faces of FcRn. Adv Immunol, 103, 77-115.
211. Ward ES, Zhou J, Ghetie V, Ober RJ. (2003). Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol, 15, 187-95.
212. Watson D. (1965). Albumin and "total globulin" fractions of blood. Adv Clin Chem, 8, 237-303.
213. Weiner LM, Surana R, Wang S. (2010). Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol, 10, 317-27.
214. West Jr AP, Bjorkman PJ. (2000). Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complexrelated Fc receptor(,). Biochemistry, 39, 9698-708.
215. West Jr AP, Herr AB, Bjorkman PJ. (2004). The chicken yolk sac IgY receptor, a functional equivalent of the mammalian MHC-related Fc receptor, is a phospholipase A2 receptor homolog. Immunity, 20, 601-10.
216. Wu AM, Senter PD. (2005). Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol, 23, 1137-46.
217. Ye L, Zeng R, Bai Y, et al. (2011). Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol, 29, 158-63.
218. Yeung YA, Leabman MK, Marvin JS, et al. (2009). Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol, 182, 7663-71.
219. Ying T, Chen W, Gong R, et al. (2012). Soluble monomeric IgG1 Fc. J Biol Chem, 287, 19399-408.
220. Yoshida M, Claypool SM, Wagner JS, et al. (2004). Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity, 20, 769-83.
221. Yoshida M, Kobayashi K, Kuo TT, et al. (2006). Neonatal Fc receptor for IgG regulates mucosal immune responses to luminal bacteria. J Clin Invest, 116, 2142-51.
222. Zalevsky J, Chamberlain AK, Horton HM, et al. (2010). Enhanced antibody half-life improves in vivo activity. Nat Biotechnol, 28, 157-9.
223. Zambidis ET, Scott DW. (1996). Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci U S A, 93, 5019-24.
224. Zhao X, Lapalombella R, Joshi T, et al. (2007). Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood, 110, 2569-77.
225. Zhou J, Johnson JE, Ghetie V, et al. (2003). Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G. J Mol Biol, 332, 901-13.
226. Zhu A, Hurst R. (2002). Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation, 9, 376-81.